Strategies for Cost-Containment: Once-Daily Ceftriaxone Plus Amikacin as Empirical Therapy for Febrile Granulocytopenic Children with Cancer

REFERENCES

• Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986; 81 (Suppl. A): S11-526.
   Google Scholar
• Schimpff SC. Overview of empiric antibiotic therapy for the febrile neutropenic patient. Rev Infect Dis 1985; 7 (Suppl. 4): S734-5740.
   Google Scholar
• Bodey GP. Empirical antibiotic therapy for fever in neu-tropenic patients. Clin Infect Dis 1993; 17 (Suppl. 2): S378-S384.
   Google Scholar
• Klastersky J. Empirical therapy for bacterial infections in granulocytopenic patients. Support Care Cancer 1994; 2: 161–168.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteremia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994; 30: 430–437.
   Web of Science ®Google Scholar
• Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lesson from four EORTC trials. Eur J Cancer din Oncol 1988; 24: 35–45.
   PubMedGoogle Scholar
• de Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granu-locytopenic cancer patients. Am J Med 1986; 80 (Suppl. Sc): S96-5100.
   Google Scholar
• Calandra T, Cometta A. Antibiotic therapy for Gram-negative bacteremia. Infect Dis Clin North Am 1991; 5: 817–834.
   PubMedGoogle Scholar
• Klastersky J. Empiric treatment of infection during gran-ulocytopenia: a comprehensive approach. Infection 1989; 17: 59–64.
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445–452.
   Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group and the GIMEMA Infection Program. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108–1115.
   Google Scholar
• del Favero A, Bucaneve GP, Menichetti F. Empiric monotherapy in neutropenia: A realistic goal? Scand J Infect Dis 1995; 36 (Suppl. 96): S34-S37.
   Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 16: 381–396.
   Google Scholar
• Boogaerts MA. Anti-infective strategies in neutropenia. J Antimicrob Chemother 1995; 36 (Suppl. A): S167-S178.
   Google Scholar
• EORTC-International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–593.
   Google Scholar
• Viscoli C, Moroni C, Boni L et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis1991; 13: 397–404.
   Google Scholar
• Viscoli C, Dudley M, Ferrea G, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27 ( Suppl. C): S113-S120.
   Google Scholar
• Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323–1332.
   PubMed Web of Science ®Google Scholar
• Washington JA, Jones RN, Gerlach EII, Murrey PR, Allen SD, Knapp CC. Multicenter comparison of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother 1993; 37: 1696-1700.
   Google Scholar
• Martino P, Girmenia C, Raccah R, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992; 49: 49–52.
   PubMed Web of Science ®Google Scholar
• Davey PG, Malek MM, Parker SE. Pharmacoeconomics of antibacterial treatment. PharmacoEconomics 1992; 6: 410–436.
   Google Scholar
• Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother 1996; 5: 375–381.
   Google Scholar
• Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992; 1: 20–32.
   PubMedGoogle Scholar
• Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother, in press.
   Google Scholar
• Petrilli AS, Melaragno R, Barros KVT, et al. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease. Pediatr Infect Dis J 1993; 12: 916–921.
   PubMed Web of Science ®Google Scholar
• Charnas R, Ridolfi Luthi A, Ruch W (Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children). Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997; 16: 346–353.
   Google Scholar
• Pession A, Prete A, Paolucci G. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empiric management of febrile granulocytopenic children with cancer. Chemotherapy 1997; 43: 358–366.
   PubMed Web of Science ®Google Scholar
• Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C. Economical aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer, in press.
   Google Scholar
• Aquino VM, Tkaczewski I, Buchanan GR. Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 1997; 25: 74–78.
   PubMed Web of Science ®Google Scholar